Caribou Biosciences, Inc. Logo

Caribou Biosciences, Inc.

Clinical-stage biopharma developing genome-edited allogeneic cell therapies.

CRBU | US

Overview

Corporate Details

ISIN(s):
US1420381089
LEI:
Country:
United States of America
Address:
2929 7TH STREET, SUITE 105, 94710 BERKELEY

Description

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing transformative, genome-edited allogeneic cell therapies. The company leverages its proprietary, next-generation CRISPR platform, chRDNA (CRISPR hybrid RNA-DNA) technology, to achieve superior specificity and precision in complex genome editing. Its primary focus is on creating 'off-the-shelf' CAR-T cell therapies for patients with hematologic malignancies and solid tumors. A key component of its strategy is 'armoring' these therapies through multiple genome-editing techniques, such as checkpoint disruption and immune cloaking, to enhance their persistence and anti-tumor activity.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Caribou Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Caribou Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Caribou Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.